Organogenesis - ORGO Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $4.83
  • Forecasted Upside: 67.82%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.88
▼ -0.12 (-4.00%)

This chart shows the closing price for ORGO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Organogenesis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ORGO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ORGO

Analyst Price Target is $4.83
▲ +67.82% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Organogenesis in the last 3 months. The average price target is $4.83, with a high forecast of $6.00 and a low forecast of $3.50. The average price target represents a 67.82% upside from the last price of $2.88.

This chart shows the closing price for ORGO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 3 polled investment analysts is to moderate buy stock in Organogenesis. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/22/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/20/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/20/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/19/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/17/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/15/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/15/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/14/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$5.00Low
2/7/2024Cantor FitzgeraldInitiated CoverageOverweight$5.00Low
12/27/2023BTIG ResearchBoost TargetBuy ➝ Buy$4.00 ➝ $6.00Low
11/14/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$3.00 ➝ $3.50Low
8/11/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$5.00 ➝ $3.00Low
8/10/2023BTIG ResearchLower TargetBuy ➝ Buy$10.00 ➝ $4.00Low
6/15/2023Morgan StanleyInitiated CoverageEqual WeightLow
5/23/2023BTIG ResearchUpgradeNeutral ➝ Buy$10.00Low
11/10/2022BTIG ResearchDowngradeBuy ➝ NeutralLow
10/20/2022BTIG ResearchLower Target$11.00Low
8/15/2022BTIG ResearchLower Target$13.00N/A
8/10/2022OppenheimerDowngradeOutperform ➝ Market PerformLow
12/10/2021BTIG ResearchInitiated CoverageBuy$24.00High
11/10/2021SVB LeerinkLower TargetOutperform$26.00 ➝ $20.00High
10/22/2021SVB LeerinkReiterated RatingOutperformMedium
9/20/2021SVB LeerinkReiterated RatingBuyHigh
8/26/2021BTIG ResearchInitiated CoverageBuy$27.00Low
8/10/2021Credit Suisse GroupBoost TargetOutperform$24.00 ➝ $25.00High
5/11/2021SVB LeerinkLower TargetOutperform$27.00 ➝ $26.00High
3/17/2021SVB LeerinkBoost TargetOutperform$19.00 ➝ $22.00High
3/12/2021Credit Suisse GroupBoost TargetOutperform$9.00 ➝ $21.00High
1/20/2021SVB LeerinkBoost TargetOutperform$10.00 ➝ $13.00High
1/14/2021BTIG ResearchBoost TargetAverage ➝ Buy$10.00 ➝ $14.00High
1/7/2021Credit Suisse GroupBoost TargetOutperform$8.00 ➝ $9.00N/A
11/18/2020SVB LeerinkBoost TargetOutperform$9.00 ➝ $10.00High
11/10/2020Credit Suisse GroupBoost TargetOutperform$7.00 ➝ $8.00Medium
10/14/2020BTIG ResearchReiterated RatingBuy$10.00High
9/21/2020OppenheimerReiterated RatingBuy$9.00Low
8/11/2020Credit Suisse GroupReiterated RatingBuy$7.00Low
8/11/2020SVB LeerinkBoost TargetOutperform$7.00 ➝ $9.00Low
7/15/2020OppenheimerInitiated CoverageBuy$8.00Medium
6/11/2020BTIG ResearchReiterated RatingBuy$8.00Medium
5/12/2020OppenheimerInitiated CoverageBuy$8.00High
5/12/2020SVB LeerinkLower TargetOutperform$8.00 ➝ $7.00High
4/8/2020BTIG ResearchLower TargetBuy$9.00 ➝ $8.00Medium
3/10/2020Credit Suisse GroupReiterated RatingBuyHigh
3/10/2020BTIG ResearchReiterated RatingBuy$9.00High
3/6/2020Credit Suisse GroupLower TargetOutperform$10.00 ➝ $8.00High
8/26/2019Credit Suisse GroupInitiated CoverageOutperformMedium
8/9/2019BTIG ResearchSet TargetBuy$12.00N/A
5/12/2019BTIG ResearchReiterated RatingBuy$12.00Low
5/2/2019BTIG ResearchReiterated RatingBuy$12.00High
5/2/2019Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$9.00High
4/17/2019CIBCInitiated CoverageOutperform ➝ Outperform$11.00Low
4/17/2019OppenheimerInitiated CoverageOutperform$11.00High
(Data available from 4/14/2019 forward)

News Sentiment Rating

0.70 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/17/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/17/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/16/2023
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/16/2023
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/15/2024
  • 7 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/14/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
3/15/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/14/2024

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Organogenesis logo
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.
Read More

Today's Range

Now: $2.88
Low: $2.79
High: $3.02

50 Day Range

MA: $3.10
Low: $2.61
High: $3.84

52 Week Range

Now: $2.88
Low: $1.79
High: $4.70

Volume

404,580 shs

Average Volume

927,278 shs

Market Capitalization

$380.04 million

P/E Ratio

72.02

Dividend Yield

N/A

Beta

1.57

Frequently Asked Questions

What sell-side analysts currently cover shares of Organogenesis?

The following sell-side analysts have issued reports on Organogenesis in the last twelve months: BTIG Research, Cantor Fitzgerald, and Morgan Stanley.
View the latest analyst ratings for ORGO.

What is the current price target for Organogenesis?

3 Wall Street analysts have set twelve-month price targets for Organogenesis in the last year. Their average twelve-month price target is $4.83, suggesting a possible upside of 67.8%. BTIG Research has the highest price target set, predicting ORGO will reach $6.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $3.50 for Organogenesis in the next year.
View the latest price targets for ORGO.

What is the current consensus analyst rating for Organogenesis?

Organogenesis currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ORGO.

What other companies compete with Organogenesis?

How do I contact Organogenesis' investor relations team?

Organogenesis' physical mailing address is 85 Dan Road, Canton MA, 02021. The company's listed phone number is (781) 575-0775 and its investor relations email address is [email protected]. The official website for Organogenesis is organogenesis.com. Learn More about contacing Organogenesis investor relations.